Carotid Plaque Imaging Project (Identification of Vulnerable Atherosclerotic Plaques With Imaging and Biological Markers)

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The rupture or erosion of an atherosclerotic plaque with thrombosis or embolization often underlie heart attacks and strokes. The early identification of patients with atherosclerotic plaques prone to rupture or erosions, vulnerable plaques (VP), and their treatment before the occurrence of events is, therefore, one of the greatest cardiovascular challenges today. Possible approaches for early detection of VP include imaging techniques allowing visualization of plaque structure, circulating biomarkers and better understanding of the pathophysiologic mechanisms of the disease. In the carotid plaque imaging project the investigators study human atherosclerotic plaques (that are removed by endarterectomy) to disclose their underlying structure and mechanisms, finding possible novel therapeutic targets or markers for VP. The investigators also study plaque structure with imaging methods and try to develop new ways to detect VP using circulating or imaging markers.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients older than 18 years old, male or female that are eligible for carotid endarterectomy due to atherosclerosis and that can provide informed consent.

Locations
Other Locations
Sweden
Skåne University Hospital (SUS)
RECRUITING
Malmo
Contact Information
Primary
Isabel Goncalves, MD, PhD
Isabel.Goncalves@med.lu.se
+46 40 331000
Time Frame
Start Date: 2005-10-26
Estimated Completion Date: 2029-12
Participants
Target number of participants: 3500
Treatments
Carotid Plaque Imaging Project (CPIP)
Related Therapeutic Areas
Sponsors
Collaborators: Swedish Foundation for Strategic Research, Skåne University Hospital funds (incl. the Medical Training and Research Agreement/ALF), Swedish Heart Lung Foundation, Region Skåne, The Swedish Research Council
Leads: Lund University

This content was sourced from clinicaltrials.gov